Hexestrol
Template:Short description Template:Short description Page Template:Infobox drug/styles.css has no content.
Page Module:Infobox/styles.css has no content.
| Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found. | |
| Clinical data | |
|---|---|
| Trade names | Synestrol, Synoestrol, Estrifar, Estronal |
| Other names | Hexoestrol; Hexanestrol; Hexanoestrol; Dihydrodiethylstilbestrol; Dihydrostilbestrol; 4,4'-(1,2-Diethylethylene)diphenol; NSC-9894 |
| Routes of administration | By mouth, intramuscular injection (as an ester) |
| Drug class | Nonsteroidal estrogen |
| Identifiers | |
| |
| CAS Number | Page Template:Plainlist/styles.css has no content. |
| PubChem CID | Page Template:Plainlist/styles.css has no content. |
| PubChem SID | Page Template:Plainlist/styles.css has no content. |
| IUPHAR/BPS | Page Template:Plainlist/styles.css has no content. |
| DrugBank | Page Template:Plainlist/styles.css has no content. |
| ChemSpider | Page Template:Plainlist/styles.css has no content. |
| UNII | Page Template:Plainlist/styles.css has no content. |
| KEGG | Page Template:Plainlist/styles.css has no content. |
| ChEBI | Page Template:Plainlist/styles.css has no content. |
| ChEMBL | Page Template:Plainlist/styles.css has no content. |
| NIAID ChemDB | Page Template:Plainlist/styles.css has no content. |
| PDB ligand | Page Template:Plainlist/styles.css has no content. |
| CompTox Dashboard (EPA) | Page Template:Plainlist/styles.css has no content. |
| Chemical and physical data | |
| Formula | C18H22O2 |
| Molar mass | 270.372 g·mol−1 |
| 3D model (JSmol) | Page Template:Plainlist/styles.css has no content. |
| |
| |
| Data page | |
| Template:Infobox drug/data page link | |
Hexestrol, sold under the brand name Synestrol among others, is a nonsteroidal estrogen which was previously used for estrogen replacement therapy and in the treatment of certain hormone-dependent cancers as well as gynecological disorders but is mostly no longer marketed.[1][2][3][4] It has also been used in the form of esters such as hexestrol diacetate (brand name Sintestrol) and hexestrol dipropionate (brand name Hexanoestrol).[1][5] Hexestrol and its esters are taken by mouth, held under the tongue, or via injection into muscle.[5][6][7]
Medical uses
Hexestrol has been used in estrogen replacement therapy, for the treatment of breast cancer in women and prostate cancer in men, and for the treatment of certain gynecological disorders.[2]
Template:Estrogen dosages for prostate cancer
Pharmacology
Pharmacodynamics
Hexestrol has approximately 302% and 234% of the affinity of estradiol for the estrogen receptors (ERs) ERα and ERβ, respectively.[8] The affinity of hexestrol for the ERs is said to be similar to or slightly higher than that of estradiol.[9] Along with diethylstilbestrol, hexestrol has been said to be one of the most potent estrogens known.[10] The total endometrial proliferation dose per cycle of different forms of hexestrol are 70 to 100 mg for oral hexestrol, 45 mg for sublingual hexestrol diacetate, and 25 mg for hexestrol dipropionate by intramuscular injection.[5] These doses are fairly similar to those of estradiol and its esters.[5] Hexestrol induces mammary gland development in rodents similarly to other estrogens.[11]
Nonsteroidal estrogens like diethylstilbestrol, which is closely related structurally to hexestrol, are known to have dramatically disproportionate estrogenic effects in the liver and on liver protein synthesis.[12]
Template:Parenteral potencies and durations of nonsteroidal estrogens
Pharmacokinetics
The pharmacokinetics and distribution of hexestrol have been studied with intravenous injection of aqueous solution in women and with subcutaneous injection of oil solution in female goats and sheep.[15][13]
Chemistry
Script error: No such module "Labelled list hatnote".
Hexestrol, also known as dihydrodiethylstilbestrol, is a synthetic nonsteroidal estrogen of the stilbestrol group related to diethylstilbestrol.[1][2] Esters of hexestrol include hexestrol diacetate, hexestrol dicaprylate, hexestrol diphosphate, and hexestrol dipropionate.[1]
History
Hexestrol was first described by Campbell, Dodds, and Lawson in 1938.[16][11][17][18] It was isolated from the demethylation products of anethole.[16][11][17][18]
Society and culture
Generic names
Hexestrol is the generic name of the drug and its INN.[1][2]
Brand names
Hexestrol has been marketed under a variety of brand names including Synestrol, Synoestrol, Estrifar, and Estronal, among others.[1][2]
Availability
Hexestrol has mostly been discontinued and remains available in only a handful of countries.[19][4] Esters of hexestrol which have been marketed include hexestrol diacetate, hexestrol dicaprylate, hexestrol diphosphate, and hexestrol dipropionate.[1]
References
Page Template:Reflist/styles.css has no content.
- ^ a b c d e f g Page Module:Citation/CS1/styles.css has no content.Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 162–. ISBN 978-1-4757-2085-3.
- ^ a b c d e Page Module:Citation/CS1/styles.css has no content.Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 140–. ISBN 978-94-011-4439-1.
- ^ Page Module:Citation/CS1/styles.css has no content.Thomas JA (12 March 1997). Endocrine Toxicology, Second Edition. CRC Press. pp. 144–. ISBN 978-1-4398-1048-4.
- ^ a b Page Module:Citation/CS1/styles.css has no content."Estradiol: Uses, Dosage & Side Effects".
- ^ a b c d Page Module:Citation/CS1/styles.css has no content.Horsky J, Presl J (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 83, 85, 145, 310. ISBN 978-94-009-8195-9.
- ^ Page Module:Citation/CS1/styles.css has no content.Thomas JA, Keenan EJ (6 December 2012). Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 153–. ISBN 978-1-4684-5036-1.
- ^ Page Module:Citation/CS1/styles.css has no content.Barar FS (2012). Textbook of Pharmacology. S. Chand Publishing. pp. 348–. ISBN 978-81-219-4080-1.
- ^ Page Module:Citation/CS1/styles.css has no content.Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA (March 1997). "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta". Endocrinology. 138 (3): 863–870. doi:10.1210/endo.138.3.4979. PMID 9048584.
- ^ Page Module:Citation/CS1/styles.css has no content.Leclercq G, Heuson JC (December 1979). "Physiological and pharmacological effects of estrogens in breast cancer". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 560 (4): 427–455. doi:10.1016/0304-419x(79)90012-x. PMID 391285.
- ^ Page Module:Citation/CS1/styles.css has no content.Solmssen UV (December 1945). "Synthetic estrogens and the relation between their structure and their activity". Chemical Reviews. 37 (3): 481–598. doi:10.1021/cr60118a004. PMID 21013428.
- ^ a b c Page Module:Citation/CS1/styles.css has no content.Campbell NR, Dodds EC, Lawson W, Noble RL (1939). "Biological effects of the synthetic œstrogen hexœstrol". The Lancet. 234 (6049): 312–313. doi:10.1016/S0140-6736(00)61997-9. ISSN 0140-6736.
- ^ Page Module:Citation/CS1/styles.css has no content.Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
- ^ a b c d Page Module:Citation/CS1/styles.css has no content.Glascock RF, Hoekstra WG (August 1959). "Selective accumulation of tritium-labelled hexoestrol by the reproductive organs of immature female goats and sheep". The Biochemical Journal. 72 (4): 673–682. doi:10.1042/bj0720673. PMC 1196992. PMID 13828338.
- ^ Page Module:Citation/CS1/styles.css has no content.Jensen EV, DeSombre ER (1972). "Mechanism of action of the female sex hormones". Annual Review of Biochemistry. 41: 203–230. doi:10.1146/annurev.bi.41.070172.001223. PMID 4563437.
- ^ Page Module:Citation/CS1/styles.css has no content.Folca PJ, Glascock RF, Irvine WT (October 1961). "Studies with tritium-labelled hexoestrol in advanced breast cancer. Comparison of tissue accumulation of hexoestrol with response to bilateral adrenalectomy and oophorectomy". Lancet. 2 (7206): 796–798. doi:10.1016/s0140-6736(61)91088-1. PMID 13893792.
- ^ a b Page Module:Citation/CS1/styles.css has no content.Campbell NR, Dodds EC, Lawson W (1938). "Œstrogenic Activity of Anol; a Highly Active Phenol Isolated from the By-Products". Nature. 142 (3608): 1121. Bibcode:1938Natur.142.1121C. doi:10.1038/1421121a0. ISSN 0028-0836. S2CID 4140616.
- ^ a b Page Module:Citation/CS1/styles.css has no content.Medicinal Chemistry. John Wiley & Sons. 1956. p. 40.
- ^ a b Page Module:Citation/CS1/styles.css has no content.Campbell NR, Dodds EC, Lawson W (1940). "The nature of the oestrogenic substances produced during the demethylation of anethole". Proceedings of the Royal Society of London. Series B, Biological Sciences. 128 (851): 253–262. Bibcode:1940RSPSB.128..253C. doi:10.1098/rspb.1940.0009. ISSN 2053-9193.
- ^ Page Module:Citation/CS1/styles.css has no content."Micromdex". Merative. Retrieved 10 March 2023.
Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.